CSF3 and rheumatoid arthritis: This could be explained because three biosimilars are available to treat rheumatoid arthritis and others are in the way to approval [30], and the recent approval process of granulocyte-colony stimulating factor biosimilars, a useful drug to treat febrile neutropenia [31].